Suggested remit: To appraise the clinical and cost effectiveness of ibrutinib in combination with corticosteroids within its marketing authorisation for untreated chronic graft versus host disease.
Following on from information provided to NICE by the company in September 2020, the appraisal of Ibrutinib with corticosteroids for untreated chronic graft versus host disease was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 3792

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
20 January 2023 Discontinued. Following on from information provided to NICE by the company in September 2020, the appraisal of Ibrutinib with corticosteroids for untreated chronic graft versus host disease was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
22 September 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of ibrutinib with corticosteroids for untreated chronic graft versus host disease. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. Following an update from the company that markets ibrutinib, NICE will not be progressing with the scoping exercise. The consultation on the draft scope will now close and the workshop arranged for Monday 12 October 2020 has been cancelled. Please accept our apologies for any inconvenience.

For further information on our processes and methods, please see our CHTE processes and methods manual